Clinical Trial Detail

NCT ID NCT03288545
Title A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

transitional cell carcinoma

Therapies

Atezolizumab + Enfortumab vedotin-ejfv + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.